DB18849InvestigationalProtein Based Therapies
Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).
- Mechanism
- Curator reviewed
Pharmacologically active on Programmed cell death protein 1
- Also known as
- Anti-pd-1 checkpoint inhibitor pf-06801591
- Code names
- PF-06801591 · RN-888
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Sasanlimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account